{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:14:10Z","timestamp":1782929650346,"version":"3.54.5"},"posted":{"date-parts":[[2026,3,26]]},"group-title":"In Review","reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,3]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background:<\/bold>\n                  Mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome) is a rare lysosomal storage disease primarily characterized by severe skeletal dysplasia. Clinical and laboratory data, including treatment responses, are reported for a cohort of Czech patients with MPS IVA.\n                  <bold>Results:<\/bold>\n                  Nineteen patients with MPS IVA from 17 families (13M\/6F) were included; only one patient exhibited a mild form. The median age at disease onset was 3.0 \u00b1 1.4 years, whereas the median age at confirmed diagnosis was 5.0 \u00b1 3.5 years. At the time of diagnosis, all patients had skeletal symptoms (pectus carinatum in 58%, short stature in 47%, hip dysplasia in 47%), and 63% had nonskeletal symptoms. Each patient underwent at least one surgical procedure (77% knee, 59% spine, 41% adenotomy). On spinal MRI, 76% of patients presented with cervical stenosis, and 41% presented with cervical myelopathy. Eight patients received ERT for a median duration of 5.5 \u00b1 2.6 years. Compared with non-ERT patients from natural history studies and non-ERT patients within our cohort, beneficial effects were evident in monitored parameters such as changes in the mean FVC and FEV1 volumes and the mean 6MWT distance. Additionally, the hidradenitis suppurativa observed in three patients improved with biologic therapy. We also describe two novel mutations (c.421_422dupTG, c.482G&gt;C).\n                  <bold>Conclusions:<\/bold>\n                  Documenting the natural history of MPS IVA in this population may aid in early diagnosis. Despite the disease's progressive nature, ERT was effective in our MPS IVA patients, demonstrating a consistent impact on endurance across all age groups.\n                <\/p>","DOI":"10.21203\/rs.3.rs-9023839\/v1","type":"posted-content","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:06:00Z","timestamp":1774530360000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-term Natural History and Elosulfase Alfa Treatment for Mucopolysaccharidosis Type IVA: A Single-Center Study in the Czech Republic"],"prefix":"10.21203","author":[{"given":"Robert","family":"\u0160\u00e1h\u00f3","sequence":"first","affiliation":[{"name":"General University Hospital in Prague: Vseobecna Fakultni Nemocnice v Praze"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Murga\u0161ov\u00e1","sequence":"additional","affiliation":[{"name":"University Hospital Kralovske Vinohrady: Fakultni Nemocnice Kralovske Vinohrady"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00e9ta","family":"Tesa\u0159ov\u00e1","sequence":"additional","affiliation":[{"name":"General University Hospital in Prague: Vseobecna Fakultni Nemocnice v Praze"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Poup\u011btov\u00e1","sequence":"additional","affiliation":[{"name":"General University Hospital in Prague: Vseobecna Fakultni Nemocnice v Praze"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Nestra\u0161il","sequence":"additional","affiliation":[{"name":"University of Minnesota Department of Psychiatry & Behavioral Sciences: University of Minnesota Twin Cities Department of Psychiatry & Behavioral Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Zeman","sequence":"additional","affiliation":[{"name":"General University Hospital in Prague: Vseobecna Fakultni Nemocnice v Praze"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5883-9509","authenticated-orcid":false,"given":"Martin","family":"Magner","sequence":"additional","affiliation":[{"name":"General University Hospital in Prague: Vseobecna Fakultni Nemocnice v Praze"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.04.002","article-title":"Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA","volume":"110","author":"Hendriksz CJ","year":"2013","unstructured":"Hendriksz CJ, Harmatz P, Beck M, Jones S, Wood T, Lachman R, et al. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab. 2013;110:54\u201364.","journal-title":"Mol Genet Metab"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","article-title":"International Morquio A Registry: clinical manifestation and natural course of Morquio A disease","volume":"30","author":"Monta\u00f1o AM","year":"2007","unstructured":"Monta\u00f1o AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165\u201374.","journal-title":"J Inherit Metab Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ymgme.2016.11.007","article-title":"Mucopolysaccharidosis IVA and glycosaminoglycans","volume":"120","author":"Khan S","year":"2017","unstructured":"Khan S, Alm\u00e9ciga-D\u00edaz CJ, Sawamoto K, Mackenzie WG, Theroux MC, Pizarro C, et al. Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab. 2017;120:78\u201395.","journal-title":"Mol Genet Metab"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10545-012-9459-0","article-title":"Clinical overview and treatment options for nonskeletal manifestations of mucopolysaccharidosis type IVA","volume":"36","author":"Hendriksz CJ","year":"2013","unstructured":"Hendriksz CJ, Al-Jawad M, Berger KI, Hawley SM, Lawrence R, Mc Ardle C, et al. Clinical overview and treatment options for nonskeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis. 2013;36:309\u201322.","journal-title":"J Inherit Metab Dis"},{"key":"ref5","first-page":"59","article-title":"Mortality in patients with morquio syndrome a","volume":"15","author":"Lavery C","year":"2015","unstructured":"Lavery C, Hendriksz C. Mortality in patients with morquio syndrome a. JIMD Rep. 2015;15:59\u201366.","journal-title":"JIMD Rep"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13023-014-0173-x","article-title":"A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases","volume":"9","author":"Leadley RM","year":"2014","unstructured":"Leadley RM, Lang S, Misso K, Bekkering T, Ross J, Akiyama T, et al. A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases. Orphanet J Rare Dis. 2014;9:173.","journal-title":"Orphanet J Rare Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13023-019-1074-9","article-title":"Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol MU","year":"2019","unstructured":"Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, et al. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14:137.","journal-title":"Orphanet J Rare Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz CJ","year":"2014","unstructured":"Hendriksz CJ, Burton B, Fleming TR, Harmatz P, Hughes D, Jones SA, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014;37:979\u201390.","journal-title":"J Inherit Metab Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymgme.2014.08.012","article-title":"Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial","volume":"114","author":"Hendriksz CJ","year":"2015","unstructured":"Hendriksz CJ, Giugliani R, Harmatz P, Mengel E, Guffon N, Valayannopoulos V, et al. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial. Mol Genet Metab. 2015;114:178\u201385.","journal-title":"Mol Genet Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2022.08.007","article-title":"Findings from the Morquio A Registry Study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase alfa","volume":"137","author":"Mitchell JJ","year":"2022","unstructured":"Mitchell JJ, Burton BK, Bober MB, Campeau PM, Cohen S, Dosenovic S, et al. Findings from the Morquio A Registry Study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase alfa. Mol Genet Metab. 2022;137:164\u201372.","journal-title":"Mol Genet Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3390\/ijms21041517","article-title":"Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management","volume":"21","author":"Sawamoto K","year":"2020","unstructured":"Sawamoto K, \u00c1lvarez Gonz\u00e1lez JV, Piechnik M, Otero FJ, Couce ML, Suzuki Y, et al. Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management. Int J Mol Sci. 2020;21:1517.","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ymgme.2014.10.015","article-title":"Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome","volume":"114","author":"Harmatz PR","year":"2015","unstructured":"Harmatz PR, Mengel KE, Giugliani R, Valayannopoulos V, Lin S-P, Parini R, et al. Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome. Mol Genet Metab. 2015;114:186\u201394.","journal-title":"Mol Genet Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-1172-9-21","article-title":"Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA","volume":"9","author":"Lin H-Y","year":"2014","unstructured":"Lin H-Y, Chuang C-K, Chen M-R, Chiu PC, Ke Y-Y, Niu D-M, et al. Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA. Orphanet J Rare Dis. 2014;9:21.","journal-title":"Orphanet J Rare Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13023-019-1105-6","article-title":"Clinical, biochemical and genetic profiles of patients with mucopolysaccharidosis type IVA (Morquio A syndrome) in Malaysia: the first national natural history cohort study","volume":"14","author":"Leong HY","year":"2019","unstructured":"Leong HY, Abdul Azize NA, Chew HB, Keng WT, Thong MK, Mohd Khalid MKN, et al. Clinical, biochemical and genetic profiles of patients with mucopolysaccharidosis type IVA (Morquio A syndrome) in Malaysia: the first national natural history cohort study. Orphanet J Rare Dis. 2019;14:143.","journal-title":"Orphanet J Rare Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/ajmg.a.61566","article-title":"Natural history of the oldest known females with mucopolysaccharidosis type IVA (Morquio A syndrome)","volume":"182","author":"Peretz RH","year":"2020","unstructured":"Peretz RH, Flora CH, Adams DJ. Natural history of the oldest known females with mucopolysaccharidosis type IVA (Morquio A syndrome). Am J Med Genet A. 2020;182:1491\u20135.","journal-title":"Am J Med Genet A"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3345\/kjp.2012.55.11.430","article-title":"Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA","volume":"55","author":"Lee NH","year":"2012","unstructured":"Lee NH, Cho SY, Maeng SH, Jeon TY, Sohn YB, Kim SJ, et al. Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA. Korean J Pediatr. 2012;55:430\u20137.","journal-title":"Korean J Pediatr"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13023-021-01675-x","article-title":"Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England","volume":"16","author":"Cleary M","year":"2021","unstructured":"Cleary M, Davison J, Gould R, Geberhiwot T, Hughes D, Mercer J, et al. Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England. Orphanet J Rare Dis. 2021;16:38.","journal-title":"Orphanet J Rare Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-018-0883-6","article-title":"Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA","volume":"13","author":"Lin H-Y","year":"2018","unstructured":"Lin H-Y, Chen M-R, Lin S-M, Hung C-L, Niu D-M, Chuang C-K, et al. Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA. Orphanet J Rare Dis. 2018;13:148.","journal-title":"Orphanet J Rare Dis"},{"key":"ref19","author":"Barbosa ICDQ","year":"2017","unstructured":"Barbosa ICDQ, Paula IS, Melo ICP, N\u00f3brega SMB, Eufrazino CSDS, Medeiros PFV. Echocardiography in Mucopolysaccharidosis Iva: Evaluation of Enzyme Replacement Therapy. Arq Bras Cardiol - IMAGEM Cardiovasc [Internet]. 2017 [cited 2025 May 19];30."},{"key":"ref20","article-title":"Real-world treatment with elosulfase alfa in patients with MPS IVA is associated with improved endurance over time","volume":"103428","author":"Burton BK","year":"2025","unstructured":"Burton BK, Stepien KM, Campeau PM, Sutton J, Hunt A, Reisewitz P et al. Real-world treatment with elosulfase alfa in patients with MPS IVA is associated with improved endurance over time. Genet Med Open. 2025;103428.","journal-title":"Genet Med Open"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s10038-019-0604-6","article-title":"Effect of enzyme replacement therapy on the growth of patients with Morquio A","volume":"64","author":"Doherty C","year":"2019","unstructured":"Doherty C, Stapleton M, Piechnik M, Mason RW, Mackenzie WG, Yamaguchi S, et al. Effect of enzyme replacement therapy on the growth of patients with Morquio A. J Hum Genet. 2019;64:625\u201335.","journal-title":"J Hum Genet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ajmg.a.32281","article-title":"Growth charts for patients affected with Morquio A disease","volume":"146A","author":"Monta\u00f1o AM","year":"2008","unstructured":"Monta\u00f1o AM, Tomatsu S, Brusius A, Smith M, Orii T. Growth charts for patients affected with Morquio A disease. Am J Med Genet A. 2008;146A:1286\u201395.","journal-title":"Am J Med Genet A"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","unstructured":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V11.5.436.436","article-title":"Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes","volume":"11","author":"Skoog WA","year":"1956","unstructured":"Skoog WA, Beck WS. Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood. 1956;11:436\u201354.","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/0003-2697(72)90094-2","article-title":"Determination of protein: A modification of the lowry method that gives a linear photometric response","volume":"48","author":"Hartree EF","year":"1972","unstructured":"Hartree EF. Determination of protein: A modification of the lowry method that gives a linear photometric response. Anal Biochem. 1972;48:422\u20137.","journal-title":"Anal Biochem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0009-8981(90)90339-T","article-title":"A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A)","volume":"187","author":"Diggelen OP","year":"1990","unstructured":"van Diggelen OP, Zhao H, Kleijer WJ, Janse HC, Poorthuis BJ, van Pelt J, et al. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A). Clin Chim Acta Int J Clin Chem. 1990;187:131\u20139.","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1007\/BF02138776","article-title":"Screening for lysosomal disorders","volume":"153","author":"Ullrich K","year":"1994","unstructured":"Ullrich K. Screening for lysosomal disorders. Eur J Pediatr. 1994;153:S38\u201343.","journal-title":"Eur J Pediatr"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Ethical Principles for Medical Research Involving Human Subjects","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310:2191.","journal-title":"JAMA"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","article-title":"The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects","volume":"109","author":"Harmatz P","year":"2013","unstructured":"Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin S-P, Parini R, et al. The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109:54\u201361.","journal-title":"Mol Genet Metab"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1006\/mgme.1999.2893","article-title":"Combined adenine phosphoribosyltransferase and N-acetylgalactosamine-6-sulfate sulfatase deficiency","volume":"68","author":"Wang L","year":"1999","unstructured":"Wang L, Ou X, Sebesta I, Vondrak K, Krijt J, Elleder M, et al. Combined adenine phosphoribosyltransferase and N-acetylgalactosamine-6-sulfate sulfatase deficiency. Mol Genet Metab. 1999;68:78\u201385.","journal-title":"Mol Genet Metab"},{"key":"ref31","first-page":"414","article-title":"[Analysis of GALNS gene mutation in thirty-eight Chinese patients with mucopolysaccharidosis type IVA]","volume":"51","author":"Ye J","year":"2013","unstructured":"Ye J, Lei H, Zhang H, Qiu W, Han L, Wang Y, et al. [Analysis of GALNS gene mutation in thirty-eight Chinese patients with mucopolysaccharidosis type IVA]. Zhonghua Er Ke Za Zhi Chin J Pediatr. 2013;51:414\u20139.","journal-title":"Zhonghua Er Ke Za Zhi Chin J Pediatr"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2013.06.008","article-title":"Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels","volume":"110","author":"D\u0169ng VC","year":"2013","unstructured":"D\u0169ng VC, Tomatsu S, Monta\u00f1o AM, Gottesman G, Bober MB, Mackenzie W, et al. Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol Genet Metab. 2013;110:129\u201338.","journal-title":"Mol Genet Metab"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/138920111795542615","article-title":"Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment","volume":"12","author":"Tomatsu S","year":"2011","unstructured":"Tomatsu S, Monta\u00f1o AM, Oikawa H, Smith M, Barrera L, Chinen Y, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12:931\u201345.","journal-title":"Curr Pharm Biotechnol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"110137","DOI":"10.1016\/j.ijporl.2020.110137","article-title":"Otorhinolaryngological manifestations in 61 patients with mucopolysaccharidosis","volume":"135","author":"Murgasova L","year":"2020","unstructured":"Murgasova L, Jurovcik M, Jesina P, Malinova V, Bloomfield M, Zeman J, et al. Otorhinolaryngological manifestations in 61 patients with mucopolysaccharidosis. Int J Pediatr Otorhinolaryngol. 2020;135:110137.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ymgme.2014.02.003","article-title":"Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses","volume":"111","author":"Lin H-Y","year":"2014","unstructured":"Lin H-Y, Shih S-C, Chuang C-K, Lee K-S, Chen M-R, Lin H-C, et al. Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses. Mol Genet Metab. 2014;111:533\u20138.","journal-title":"Mol Genet Metab"},{"key":"ref36","first-page":"518","article-title":"Hearing patterns in Morquio\u2019s syndrome (mucopolysaccharidosis IV)","volume":"103","author":"Riedner ED","year":"1977","unstructured":"Riedner ED, Levin LS. Hearing patterns in Morquio\u2019s syndrome (mucopolysaccharidosis IV). Arch Otolaryngol Chic Ill 1960. 1977;103:518\u201320.","journal-title":"Arch Otolaryngol Chic Ill 1960"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/diagnostics10080554","article-title":"Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions","volume":"10","author":"Wolfberg J","year":"2020","unstructured":"Wolfberg J, Chintalapati K, Tomatsu S, Nagao K. Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions. Diagnostics. 2020;10:554.","journal-title":"Diagnostics"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jdcr.2025.04.043","article-title":"Mucopolysaccharidosis type IVA and severe hidradenitis suppurativa: A case series","volume":"62","author":"Fialov\u00e1 J","year":"2025","unstructured":"Fialov\u00e1 J, Kojanov\u00e1 M, \u0160\u00e1h\u00f3 R, Magner M. Mucopolysaccharidosis type IVA and severe hidradenitis suppurativa: A case series. JAAD Case Rep. 2025;62:146\u201350.","journal-title":"JAAD Case Rep"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00381-018-3823-9","article-title":"Outcomes from 18 years of cervical spine surgery in MPS IVA: a single centre\u2019s experience","volume":"34","author":"Broomfield A","year":"2018","unstructured":"Broomfield A, Zuberi K, Mercer J, Moss G, Finnegan N, Hensman P, et al. Outcomes from 18 years of cervical spine surgery in MPS IVA: a single centre\u2019s experience. Childs Nerv Syst. 2018;34:1705\u201316.","journal-title":"Childs Nerv Syst"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"17529","DOI":"10.1038\/s41598-020-70297-3","article-title":"HARDI-ZOOMit protocol improves specificity to microstructural changes in presymptomatic myelopathy","volume":"10","author":"Labounek R","year":"2020","unstructured":"Labounek R, Valo\u0161ek J, Hor\u00e1k T, Sv\u00e1tkov\u00e1 A, Bedna\u0159\u00edk P, Vojt\u00ed\u0161ek L, et al. HARDI-ZOOMit protocol improves specificity to microstructural changes in presymptomatic myelopathy. Sci Rep. 2020;10:17529.","journal-title":"Sci Rep"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"imaga00559","DOI":"10.1162\/imag_a_00559","article-title":"Body size and intracranial volume interact with the structure of the central nervous system: A multi-center in vivo neuroimaging study","volume":"3","author":"Labounek R","year":"2025","unstructured":"Labounek R, Bondy MT, Paulson AL, B\u00e9dard S, Abramovic M, Alonso-Ortiz E, et al. Body size and intracranial volume interact with the structure of the central nervous system: A multi-center in vivo neuroimaging study. Imaging Neurosci. 2025;3:imaga00559.","journal-title":"Imaging Neurosci"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/humu.24270","article-title":"Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): A review and classification of GALNS gene variants and reporting of 68 novel variants","volume":"42","author":"Zanetti A","year":"2021","unstructured":"Zanetti A, D\u2019Avanzo F, AlSayed M, Brusius-Facchin AC, Chien Y, Giugliani R, et al. Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): A review and classification of GALNS gene variants and reporting of 68 novel variants. Hum Mutat. 2021;42:1384\u201398.","journal-title":"Hum Mutat"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13353-019-00491-1","article-title":"Novel data on growth phenotype and causative genotypes in 29 patients with Morquio (Morquio-Brailsford) syndrome from Central-Eastern Europe","volume":"60","author":"Jezela-Stanek A","year":"2019","unstructured":"Jezela-Stanek A, R\u00f3\u017cd\u017cy\u0144ska-\u015awi\u0105tkowska A, Kulpanovich A, Ciara E, Marucha J, Tylki-Szyma\u0144ska A. Novel data on growth phenotype and causative genotypes in 29 patients with Morquio (Morquio-Brailsford) syndrome from Central-Eastern Europe. J Appl Genet. 2019;60:163\u201374.","journal-title":"J Appl Genet"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/(SICI)1098-1004(1996)7:2<123::AID-HUMU6>3.0.CO;2-D","article-title":"Mucopolysaccharidosis IVA: submicroscopic deletion of 16q24.3 and a novel R386C mutation of N-acetylgalactosamine-6-sulfate sulfatase gene in a classical Morquio disease","volume":"7","author":"Fukuda S","year":"1996","unstructured":"Fukuda S, Tomatsu S, Masuno M, Ogawa T, Yamagishi A, Rezvi GM, et al. Mucopolysaccharidosis IVA: submicroscopic deletion of 16q24.3 and a novel R386C mutation of N-acetylgalactosamine-6-sulfate sulfatase gene in a classical Morquio disease. Hum Mutat. 1996;7:123\u201334.","journal-title":"Hum Mutat"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10545-016-9973-6","article-title":"Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome","volume":"39","author":"Hendriksz CJ","year":"2016","unstructured":"Hendriksz CJ, Berger KI, Parini R, AlSayed MD, Raiman J, Giugliani R, et al. Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome. J Inherit Metab Dis. 2016;39:839\u201347.","journal-title":"J Inherit Metab Dis"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2016.05.018","article-title":"Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome","volume":"119","author":"Hendriksz CJ","year":"2016","unstructured":"Hendriksz CJ, Parini R, AlSayed MD, Raiman J, Giugliani R, Solano Villarreal ML, et al. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome. Mol Genet Metab. 2016;119:131\u201343.","journal-title":"Mol Genet Metab"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/ijms21082975","article-title":"Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations","volume":"21","author":"Parini R","year":"2020","unstructured":"Parini R, Deodato F. Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations. Int J Mol Sci. 2020;21:2975.","journal-title":"Int J Mol Sci"},{"key":"ref48","first-page":"116","article-title":"Elosulfase alfa for mucopolysaccharidosis type IVA: Real-world experience in 7 patients from the Spanish Morquio-A early access program","volume":"15","author":"Pintos-Morell G","year":"2018","unstructured":"Pintos-Morell G, Blasco-Alonso J, Couce ML, Guti\u00e9rrez-Solana LG, Guill\u00e9n-Navarro E, O\u2019Callaghan M, et al. Elosulfase alfa for mucopolysaccharidosis type IVA: Real-world experience in 7 patients from the Spanish Morquio-A early access program. Mol Genet Metab Rep. 2018;15:116\u201320.","journal-title":"Mol Genet Metab Rep"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.pedneo.2018.08.005","article-title":"Long-term effects of enzyme replacement therapy for Taiwanese patients with mucopolysaccharidosis IVA","volume":"60","author":"Lin H-Y","year":"2019","unstructured":"Lin H-Y, Chuang C-K, Ke Y-Y, Hsu C-C, Chiu PC, Niu D-M, et al. Long-term effects of enzyme replacement therapy for Taiwanese patients with mucopolysaccharidosis IVA. Pediatr Neonatol. 2019;60:342\u20133.","journal-title":"Pediatr Neonatol"},{"key":"ref50","first-page":"42","article-title":"30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case","volume":"9","author":"Do Cao J","year":"2016","unstructured":"Do Cao J, Wiedemann A, Quinaux T, Battaglia-Hsu SF, Mainard L, Froissart R, et al. 30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case. Mol Genet Metab Rep. 2016;9:42\u20135.","journal-title":"Mol Genet Metab Rep"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-021-01761-0","article-title":"Morquio A syndrome and effect of enzyme replacement therapy in different age groups of Turkish patients: a case series","volume":"16","author":"K\u0131lavuz S","year":"2021","unstructured":"K\u0131lavuz S, Basaran S, Kor D, Bulut FD, Erdem S, Ball\u0131 HT, et al. Morquio A syndrome and effect of enzyme replacement therapy in different age groups of Turkish patients: a case series. Orphanet J Rare Dis. 2021;16:144.","journal-title":"Orphanet J Rare Dis"},{"key":"ref52","first-page":"100487","article-title":"The characterisation of pulmonary function in patients with mucopolysaccharidoses IVA: A longitudinal analysis","volume":"20","author":"Kenth JJ","year":"2019","unstructured":"Kenth JJ, Thompson G, Fullwood C, Wilkinson S, Jones S, Bruce IA. The characterisation of pulmonary function in patients with mucopolysaccharidoses IVA: A longitudinal analysis. Mol Genet Metab Rep. 2019;20:100487.","journal-title":"Mol Genet Metab Rep"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"e0162612","DOI":"10.1371\/journal.pone.0162612","article-title":"Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome). Jefferies JL","volume":"11","author":"Kampmann C","year":"2016","unstructured":"Kampmann C, Abu-Tair T, G\u00f6kce S, Lampe C, Reinke J, Mengel E, et al. Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome). Jefferies JL. editor PLOS ONE. 2016;11:e0162612.","journal-title":"editor PLOS ONE"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/diagnostics10020108","article-title":"Long-Term Outcomes of Early Enzyme Replacement Therapy for Mucopolysaccharidosis IV: Clinical Case Studies of Two Siblings","volume":"10","author":"Barak S","year":"2020","unstructured":"Barak S, Anikster Y, Sarouk I, Stern E, Eisenstein E, Yissar T, et al. Long-Term Outcomes of Early Enzyme Replacement Therapy for Mucopolysaccharidosis IV: Clinical Case Studies of Two Siblings. Diagnostics. 2020;10:108.","journal-title":"Diagnostics"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/pr.2015.169","article-title":"Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y","volume":"78","author":"Jones SA","year":"2015","unstructured":"Jones SA, Bialer M, Parini R, Martin K, Wang H, Yang K, et al. Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y. Pediatr Res. 2015;78:717\u201322.","journal-title":"Pediatr Res"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9023839\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9023839\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:34:45Z","timestamp":1782927285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9023839\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":55,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9023839\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s13023-026-04439-7","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,3,26]]},"subtype":"preprint"}}